News brief
On 2026/3/26, TechCrunch reported that VITL, a prescribing platform for cash-pay clinics, completed USD 7.5 million in funding and exceeded USD 10 million in annual recurring revenue, benefiting from demand for GLP-1 drugs.
Connected profiles
Explore
Sources · 1Sources & provenance
English text is maintained separately from the original record. Consult the original source before citing a fact.
- techcrunch.com ↗Published Mar 26, 2026
Original source text
Names may use phonetic renderings when no English name is supplied. The original wording is retained below.
2026年3月26日，据TechCrunch报道，现金支付诊所开方平台VITL完成750万美元融资，年化经常性收入超过1000万美元，受益于GLP-1类药物热潮。